Flagellin as an adjuvant: Cellular mechanisms and potential

Journal of Immunology

Volumn 185, Issue 10, 2010, Pages 5677-5682

  Mizel, Steven B ^a   Bates, John T ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; ENDOTOXIN; FLAGELLIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 6; NUCLEIC ACID; OVALBUMIN; RECOMBINANT VACCINE; SUPPRESSOR OF CYTOKINE SIGNALING 1; TETANUS TOXOID; TOLL LIKE RECEPTOR 5; WEST NILE VACCINE;

ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; YERSINIA PESTIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FLAGELLIN; HUMANS;

EID: 78650648694     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002156     Document Type: Article

References (76)

1. Ciacci-Woolwine, F., I. C. Blomfield, S. H. Richardson, and S. B. Mizel. 1998. Salmonella flagellin induces tumor necrosis factor alpha in a human promonocytic cell line. Infect. Immun. 66:1127-1134.
2. Moors, M. A., L. Li, and S. B. Mizel. 2001. Activation of interleukin-1 receptor-associated kinase by gram-negative flagellin. Infect. Immun. 69:4424-4429.
3. Hayashi, F., K. D. Smith, A. Ozinsky, T. R. Hawn, E. C. Yi, D. R. Goodlett, J. K. Eng, S. Akira, D. M. Underhill, and A. Aderem. 2001. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410:1099-1103.
4. Gewirtz, A. T., T. A. Navas, S. Lyons, P. J. Godowski, and J. L. Madara. 2001. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J. Immunol. 167:1882-1885.
5. Mizel, S. B., and J. A. Snipes. 2002. Gram-negative flagellin-induced self-tolerance is associated with a block in interleukin-1 receptor-associated kinase release from toll-like receptor 5. J. Biol. Chem. 277:22414-22420.
6. Franchi, L., A. Amer, M. Body-Malapel, T. D. Kanneganti, N. Ozören, R. Jagirdar, N. Inohara, P. Vandenabeele, J. Bertin, A. Coyle, et al. 2006. Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1β in salmonella-infected macrophages. Nat. Immunol. 7:576-582.
7. Miao, E. A., C. M. Alpuche-Aranda, M. Dors, A. E. Clark, M. W. Bader, S. I. Miller, and A. Aderem. 2006. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf. Nat. Immunol. 7:569-575.
8. Lightfield, K. L., J. Persson, S. W. Brubaker, C. E. Witte, J. von Moltke, E. A. Dunipace, T. Henry, Y. H. Sun, D. Cado, W. F. Dietrich, et al. 2008. Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin. Nat. Immunol. 9:1171-1178.
9. Donnelly, M. A., and T. S. Steiner. 2002. Two nonadjacent regions in enter-oaggregative Escherichia coli flagellin are required for activation of toll-like receptor 5. J. Biol. Chem. 277:40456-40461.
10. Eaves-Pyles, T. D., H. R. Wong, K. Odoms, and R. B. Pyles. 2001. Salmonella flagellin-dependent proinflammatory responses are localized to the conserved amino and carboxyl regions of the protein. J. Immunol. 167:7009-7016.
11. Murthy, K. G. K., A. Deb, S. Goonesekera, C. Szabó, and A. L. Salzman. 2004. Identification of conserved domains in Salmonella muenchen flagellin that are essential for its ability to activate TLR5 and to induce an inflammatory response in vitro. J. Biol. Chem. 279:5667-5675.
12. Honko, A. N., and S. B. Mizel. 2005. Effects of flagellin on innate and adaptive immunity. Immunol. Res. 33:83-101.
13. Ben-Yedidia, T., and R. Arnon. 1998. Effect of pre-existing carrier immunity on the efficacy of synthetic influenza vaccine. Immunol. Lett. 64:9-15.
14. Ben-Yedidia, T., R. Tarrab-Hazdai, D. Schechtman, and R. Arnon. 1999. Intranasal administration of synthetic recombinant peptide-based vaccine protects mice from infection by Schistosoma mansoni. Infect. Immun. 67:4360-4366.
15. Ben-Yedidia, T., H. Marcus, Y. Reisner, and R. Arnon. 1999. Intranasal administration of peptide vaccine protects human/mouse radiation chimera from influenza infection. Int. Immunol. 11:1043-1051.
16. Ben-Yedidia, T., L. Abel, R. Arnon, and A. Globerson. 1998. Efficacy of anti-influenza peptide vaccine in aged mice. Mech. Ageing Dev. 104:11-23.
17. Jeon, S. H., T. Ben-Yedidia, and R. Arnon. 2002. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine 20:2772-2780.
18. Levi, R., and R. Arnon. 1996. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine 14:85-92.
19. McEwen, J., R. Levi, R. J. Horwitz, and R. Arnon. 1992. Synthetic recombinant vaccine expressing influenza haemagglutinin epitope in Salmonella flagellin leads to partial protection in mice. Vaccine 10:405-411.
20. Honko, A. N., N. Sriranganathan, C. J. Lees, and S. B. Mizel. 2006. Flagellin is an effective adjuvant for immunization against lethal respiratory challenge with Yersinia pestis. Infect. Immun. 74:1113-1120.
21. McDermott, P. F., F. Ciacci-Woolwine, J. A. Snipes, and S. B. Mizel. 2000. High-affinity interaction between gram-negative flagellin and a cell surface polypeptide results in human monocyte activation. Infect. Immun. 68:5525-5529.
22. Mizel, S. B., A. P. West, and R. R. Hantgan. 2003. Identification of a sequence in human toll-like receptor 5 required for the binding of Gram-negative flagellin. J. Biol. Chem. 278:23624-23629.
23. Adar, Y., Y. Singer, R. Levi, E. Tzehoval, S. Perk, C. Banet-Noach, S. Nagar, R. Arnon, and T. Ben-Yedidia. 2009. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27:2099-2107.
24. Lee, L. H., E. Burg III, S. Baqar, A. L. Bourgeois, D. H. Burr, C. P. Ewing, T. J. Trust, and P. Guerry. 1999. Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect. Immun. 67:5799-5805.
25. das Graças Luna, M., F. F. Sardella, and L. C. Ferreira. 2000. Salmonella flagellin fused with a linear epitope of colonization factor antigen I (CFA/I) can prime antibody responses against homologous and heterologous fimbriae of enterotoxigenic Escherichia coli. Res. Microbiol. 151:575-582.
26. Pereira, C. M., B. E. Guth, M. E. Sbrogio-Almeida, and B. A. Castilho. 2001. Antibody response against Escherichia coli heat-stable enterotoxin expressed as fusions to flagellin. Microbiology 147:861-867.
27. Cuadros, C., F. J. Lopez-Hernandez, A. L. Dominguez, M. McClelland, and J. Lustgarten. 2004. Flagellin fusion proteins as adjuvants or vaccines induce specific immune responses. Infect. Immun. 72:2810-2816.
28. Strindelius, L., M. Filler, and I. Sjöholm. 2004. Mucosal immunization with purified flagellin from Salmonella induces systemic and mucosal immune responses in C3H/HeJ mice. Vaccine 22:3797-3808.
29. McSorley, S. J., B. T. Cookson, and M. K. Jenkins. 2000. Characterization of CD4+ T cell responses during natural infection with Salmonella typhimurium. J. Immunol. 164:986-993.
30. Pino, O., M. Martin, and S. M. Michalek. 2005. Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses. Infect. Immun. 73:6763-6770.
31. Lee, S. E., S. Y. Kim, B. C. Jeong, Y. R. Kim, S. J. Bae, O. S. Ahn, J. J. Lee, H. C. Song, J. M. Kim, H. E. Choy, et al. 2006. A bacterial flagellin, Vibrio vul-nificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect. Immun. 74:694-702.
32. Huleatt, J. W., A. R. Jacobs, J. Tang, P. Desai, E. B. Kopp, Y. Huang, L. Song, V. Nakaar, and T. J. Powell. 2007. Vaccination with recombinant fusion proteins incorporating Toll-like receptor ligands induces rapid cellular and humoral immunity. Vaccine 25:763-775.
33. McDonald, W. F., J. W. Huleatt, H. G. Foellmer, D. Hewitt, J. Tang, P. Desai, A. Price, A. Jacobs, V. N. Takahashi, Y. Huang, et al. 2007. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity. J. Infect. Dis. 195:1607-1617.
34. Lee, S. E., Y. I. Koh, M. K. Kim, Y. R. Kim, S. Y. Kim, J. H. Nam, Y. D. Choi, S. J. Bae, Y. J. Ko, H. J. Ryu, et al. 2008. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J. Clin. Immunol. 28:157-165.
35. Song, L., Y. Zhang, N. E. Yun, A. L. Poussard, J. N. Smith, J. K. Smith, V. Borisevich, J. J. Linde, M. A. Zacks, H. Li, et al. 2009. Superior efficacy of a recombinant flagellin:H5N1 HA globular head vaccine is determined by the placement of the globular head within flagellin. Vaccine 27:5875-5884.
36. Bargieri, D. Y., J. A. Leite, S. C. Lopes, M. E. Sbrogio-Almeida, C. J. M. Braga, L. C. Ferreira, I. S. Soares, F. T. Costa, and M. M. Rodrigues. 2010. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium. Vaccine 28:2818-2826.
37. Bargieri, D. Y., D. S. Rosa, C. J. M. Braga, B. O. Carvalho, F. T. M. Costa, N. M. Espíndola, A. J. Vaz, I. S. Soares, L. C. Ferreira, and M. M. Rodrigues. 2008. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26:6132-6142.
38. + T cell adjuvant effects of Salmonella FliCd flagellin in live vaccine vectors or as purified protein. Vaccine 28:1373-1382.
39. Huleatt, J. W., V. Nakaar, P. Desai, Y. Huang, D. Hewitt, A. Jacobs, J. Tang, W. McDonald, L. Song, R. K. Evans, et al. 2008. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26:201-214.
40. Mizel, S. B., A. Graff, N. Sriranganathan, S. Ervin, C. J. Lees, M. O. Lively, R. R. Hantgan, M. J. Thomas, J. Wood, and B. Bell. 2009. Flagellin-F1-V fusion protein is an effective plague vaccine in mice and two species of nonhuman primates. Clin. Vaccine Immunol. 16:21-28.
41. Weimer, E. T., H. Lu, N. D. Kock, D. J. Wozniak, and S. B. Mizel. 2009. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa. Infect. Immun. 77:2356-2366.
42. Weimer, E. T., S. E. Ervin, D. J. Wozniak, and S. B. Mizel. 2009. Immunization of young African green monkeys with OprF epitope 8-OprI-type A-and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa. Vaccine 27:6762-6769.
43. Delaney, K. N., J. P. Phipps, J. B. Johnson, and S. B. Mizel. 2010. A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice. Viral Immunol. 23:201-210.
44. + cells is necessary for the adjuvant activity of flagellin. J. Immunol. 182:7539-7547.
45. Honko, A. N., and S. B. Mizel. 2004. Mucosal administration of flagellin induces innate immunity in the mouse lung. Infect. Immun. 72:6676-6679.
46. Sixt, M., N. Kanazawa, M. Selg, T. Samson, G. Roos, D. P. Reinhardt, R. Pabst, M. B. Lutz, and L. Sorokin. 2005. The conduit system transports soluble antigens from the afferent lymph to resident dendritic cells in the T cell area of the lymph node. Immunity 22:19-29.
47. Sanders, C. J., D. A. Moore III, I. R. Williams, and A. T. Gewirtz. 2008. Both radioresistant and hemopoietic cells promote innate and adaptive immune responses to flagellin. J. Immunol. 180:7184-7192.
48. Pegu, A., S. Qin, B. A. Fallert Junecko, R. E. Nisato, M. S. Pepper, and T. A. Reinhart. 2008. Human lymphatic endothelial cells express multiple functional TLRs. J. Immunol. 180:3399-3405.
49. Maaser, C., J. Heidemann, C. von Eiff, A. Lugering, T. W. Spahn, D. G. Binion, W. Domschke, N. Lugering, and T. Kucharzik. 2004. Human intestinal micro-vascular endothelial cells express Toll-like receptor 5: a binding partner for bacterial flagellin. J. Immunol. 172:5056-5062.
50. Bates, J. T., A. N. Honko, A. H. Graff, N. D. Kock, and S. B. Mizel. 2008. Mucosal adjuvant activity of flagellin in aged mice. Mech. Ageing Dev. 129:271-281.
51. Benko, S., Z. Magyarics, A. Szabó, and E. Rajnavölgyi. 2008. Dendritic cell subtypes as primary targets of vaccines: the emerging role and cross-talk of pattern recognition receptors. Biol. Chem. 389:469-485.
52. Tsujimoto, H., T. Uchida, P. A. Efron, P. O. Scumpia, A. Verma, T. Matsumoto, S. K. Tschoeke, R. F. Ungaro, S. Ono, S. Seki, et al. 2005. Flagellin enhances NK cell proliferation and activation directly and through dendritic cell-NK cell interactions. J. Leukoc. Biol. 78:888-897.
53. Vicente-Suarez, I., J. Brayer, A. Villagra, F. Cheng, and E. M. Sotomayor. 2009. TLR5 ligation by flagellin converts tolerogenic dendritic cells into activating antigen-presenting cells that preferentially induce T-helper 1 responses. Immunol. Lett. 125:114-118.
54. Didierlaurent, A., I. Ferrero, L. A. Otten, B. Dubois, M. Reinhardt, H. Carlsen, R. Blomhoff, S. Akira, J.-P. Kraehenbuhl, and J.-C. Sirard. 2004. Flagellin promotes myeloid differentiation factor 88-dependent development of Th2-type response. J. Immunol. 172:6922-6930.
55. Datta, S. K., V. Redecke, K. R. Prilliman, K. Takabayashi, M. Corr, T. Tallant, J. DiDonato, R. Dziarski, S. Akira, S. P. Schoenberger, and E. Raz. 2003. A subset of Toll-like receptor ligands induces cross-presentation by bone marrow-derived dendritic cells. J. Immunol. 170:4102-4110.
56. Means, T. K., F. Hayashi, K. D. Smith, A. Aderem, and A. D. Luster. 2003. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J. Immunol. 170:5165-5175.
57. Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, and B. Pulendran. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984-4989.
58. Arimilli, S., J. B. Johnson, K. M. Clark, A. H. Graff, M. A. Alexander-Miller, S. B. Mizel, and G. D. Parks. 2008. Engineered expression of the TLR5 ligand flagellin enhances paramyxovirus activation of human dendritic cell function. J. Virol. 82:10975-10985.
59. Salazar-Gonzalez, R.-M., A. Srinivasan, A. Griffin, G. Muralimohan, J. M. Ertelt, R. Ravindran, A. T. Vella, and S. J. McSorley. 2007. Salmonella flagellin induces bystander activation of splenic dendritic cells and hinders bacterial replication in vivo. J. Immunol. 179:6169-6175.
60. West, A. P., B. A. Dancho, and S. B. Mizel. 2005. Gangliosides inhibit flagellin signaling in the absence of an effect on flagellin binding to toll-like receptor 5. J. Biol. Chem. 280:9482-9488.
61. Ciacci-Woolwine, F., P. F. McDermott, and S. B. Mizel. 1999. Induction of cytokine synthesis by flagella from gram-negative bacteria may be dependent on the activation or differentiation state of human monocytes. Infect. Immun. 67:5176-5185.
62. Uematsu, S., K. Fujimoto, M. H. Jang, B.-G. Yang, Y.-J. Jung, M. Nishiyama, S. Sato, T. Tsujimura, M. Yamamoto, Y. Yokota, et al. 2008. Regulation of humoral and cellular gut immunity by lamina propria dendritic cells expressing Toll-like receptor 5. Nat. Immunol. 9:769-776.
63. + T cells. J. Immunol. 175:1551-1557.
64. Crellin, N. K., R. V. Garcia, O. Hadisfar, S. E. Allan, T. S. Steiner, and M. K. Levings. 2005. Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells. J. Immunol. 175:8051-8059.
65. Simone, R., A. Floriani, and D. Saverino. 2009. Stimulation of human CD4 T lymphocytes via TLR3, TLR5 and TLR7/8 up-regulates expression of costimu-latory and modulates proliferation. Open Microbiol. J. 3:1-8.
66. McCarron, M., and D. J. Reen. 2009. Activated human neonatal CD8+ T cells are subject to immunomodulation by direct TLR2 or TLR5 stimulation. J. Immunol. 182:55-62.
67. Okugawa, S., S. Yanagimoto, K. Tsukada, T. Kitazawa, K. Koike, S. Kimura, H. Nagase, K. Hirai, and Y. Ota. 2006. Bacterial flagellin inhibits T cell receptor-mediated activation of T cells by inducing suppressor of cytokine signalling-1 (SOCS-1). Cell. Microbiol. 8:1571-1580.
68. Pasare, C., and R. Medzhitov. 2005. Control of B-cell responses by Tolllike receptors. Nature 438:364-368.
69. Sanders, C. J., Y. Yu, D. A. Moore III, I. R. Williams, and A. T. Gewirtz. 2006. Humoral immune response to flagellin requires T cells and activation of innate immunity. J. Immunol. 177:2810-2818.
70. Chauhan, N., R. Kumar, J. Badhai, A. Preet, and P. K. Yadava. 2005. Immuno-genicity of cholera toxin B epitope inserted in Salmonella flagellin expressed on bacteria and administered as DNA vaccine. Mol. Cell. Biochem. 276:1-6.
71. Cunningham, A. F., M. Khan, J. Ball, K.-M. Toellner, K. Serre, E. Mohr, and C. M. MacLennan. 2004. Responses to the soluble fagellar protein FliC are Th2, while those to FliC on Salmonella are Th1. Eur. J. Immunol. 34:2986-2995.
72. Schwarz, K., T. Storni, V. Manolova, A. Didierlaurent, J.-C. Sirard, P. Röthlisberger, and M. F. Bachmann. 2003. Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur. J. Immunol. 33:1465-1470.
73. Sambhara, S., and J. E. McElhaney. 2009. Immunosenescence and influenza vaccine efficacy. Curr. Top. Microbiol. Immunol. 333:413-429.
74. Wang, B. Z., F. S. Quan, S. M. Kang, J. Bozja, I. Skountzou, and R. W. Compans. 2008. Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses. J. Virol. 82:11813-11823.
75. Salman, H. H., J. M. Irache, and C. Gamazo. 2009. Immunoadjuvant capacity of flagellin and mannosamine-coated poly (anhydride) nanoparticles in oral vaccination. Vaccine 27:4784-4790.
76. Synnott, A., K. Ohshima, Y. Nakai, and Y. Tanji. 2009. IgA response of BALB/c mice to orally administered Salmonella typhimurium flagellin-displaying T2 bacter-iophages. Biotechnol. Prog. 25:552-558.